5-Amino 1MQ is an experimental NNMT (nicotinamide N-methyltransferase) inhibitor. Most of its reported benefits come from cell and animal studies, with very limited human clinical evidence available so far.
1. Reduced Body Fat
The most studied benefit is fat loss.
Research in obese mice found that inhibiting NNMT with 5-Amino 1MQ reduced fat mass and fat-cell size without reducing food intake, suggesting the effect is metabolic rather than appetite-driven.
Potential effects:
- Reduced white adipose tissue
- Smaller fat cells
- Improved body composition
Possible reduction in visceral fat accumulation
2. Increased Energy Expenditure
NNMT inhibition appears to shift fat cells from “energy storage” toward “energy burning.”
Potential benefits include:
- Higher resting metabolic rate
- Increased fatty-acid oxidation
- Greater mitochondrial activity
- Enhanced calorie expenditure at rest
3. Higher NAD⁺ Availability
NNMT normally consumes nicotinamide, a precursor needed to produce NAD⁺.
By blocking NNMT, 5-Amino 1MQ may:
- Preserve nicotinamide
- Increase intracellular NAD⁺ levels
- Support cellular energy production
- Enhance mitochondrial function
This mechanism has led some researchers to compare it conceptually with NAD⁺-boosting approaches such as NMN or NR, although it works differently.
4. Improved Insulin Sensitivity
Animal studies suggest NNMT inhibition may improve:
- Insulin sensitivity
- Glucose tolerance
- Fasting blood glucose control
- Metabolic flexibility
This has generated interest in potential applications for obesity and metabolic syndrome.
5. Muscle Preservation During Fat Loss
Unlike severe calorie restriction, preclinical studies suggest fat reduction may occur with minimal loss of lean mass. Some animal research has also reported improved muscle stem-cell activity and muscle function.
Potential benefits:
- Better body recomposition
- Preservation of muscle during dieting
- Improved muscle regeneration in aging models
6. Potential Liver Health Benefits
Recent obesity-model research has suggested improvements in markers associated with fatty liver disease when NNMT is inhibited. This area remains early-stage but is scientifically interesting because obesity, insulin resistance, and fatty liver are closely linked.
7. Potential Healthy Aging Effects
Because NAD⁺ levels, mitochondrial function, and SIRT1 activity are associated with cellular aging, researchers are exploring whether NNMT inhibition could have broader longevity-related benefits. At present, these remain theoretical and preclinical.
Evidence Strength
| Benefit | Evidence Level |
| Fat loss | Moderate (animal studies) |
| Increased metabolism | Moderate (animal studies) |
| Increased NAD⁺ | Moderate (mechanistic and animal data) |
| Improved insulin sensitivity | Moderate (animal studies) |
| Muscle preservation | Preliminary |
| Liver health support | Preliminary |
| Longevity/anti-aging | Speculative |
Key Limitation
The major caveat is that there are currently no large, high-quality human clinical trials demonstrating that 5-Amino 1MQ produces the same benefits in humans as it does in animal models. Most claims are extrapolated from mechanistic research and rodent studies.
Bottom Line
The strongest evidence for 5-Amino 1MQ suggests it may:
- Increase NAD⁺ availability.
- Improve fat-cell metabolism.
- Increase energy expenditure.
- Reduce body fat while preserving lean mass.
- Improve insulin sensitivity.
Among these, fat loss, metabolic enhancement, and NAD⁺ preservation are currently the most scientifically supported potential benefits, though confirmation in human clinical trials is still needed.